Fig. 5: Early signals of clinical efficacy in patients with MSS-CRC in advanced disease setting.
a, Scatter plot showing tumor sample RNA sequencing (RNA-seq) for patients before study treatment. PD-L1 normalized RNA-sequencing expected counts (y axis) versus tumor mutational burden (x axis) for patients and relevant TCGA cancer types. b, Patient RNA-sequencing IFN-γ signature average z-scores (x axis) calculated across patients and relevant TCGA cancer types (y axis). TCGA samples: MSS-CRC (n = 286), MSI-CRC (n = 62), gastric (n = 406), lung adenocarcinoma (Lung Ad.)_ (n = 498), lung squamous (Lung Sq.) (n = 463) and melanoma (n = 436). GRANITE patients: MSS-CRC (n = 7), GEA (n = 6) and NSCLC (n = 1). c, Percent change in ctDNA following initiation of study treatment relative to baseline levels shown as best response and colored by RECIST-based response and time on treatment. Patients in blue were all on study treatment >24 weeks with two patients treated beyond RECIST-based progressive disease (PD) that was not confirmed by 24 weeks and continued on study treatment. d, Probability of survival in MSS-CRC patients with (n = 4) or without (n = 3) reduction in ctDNA since ChAd68 prime. Data cutoff 31 January 2022. e, Radiological images showing tumor lesions in the lung and liver of patient G8 before initiating study treatment (baseline) and following study treatment (16 and 48 weeks). Fluorodeoxyglucose-positron emission tomography imaging of tumor lesions in the liver when patient was diagnosed in February 2018 and 7 months after starting study treatment. Arrows indicate relevant target lesions.
